Obinutuzumab 1g/40ml solution for infusion vials
Requires a prescription from a doctor or prescriber
Drugs affecting the immune response
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Obinutuzumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Obinutuzumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Obinutuzumab on the MHRA register
Gazyvaro 1000mg/40ml concentrate for solution for infusion vials
WHO defined daily dose (DDD)
35.7 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Obinutuzumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(12)
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) (TA702)
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) (TA978)
Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Venetoclax for treating chronic lymphocytic leukaemia (TA796)
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
81 found
Half-life
25.5 days
Mechanism
Obinutuzumab is a CD20-directed cytolytic antibody.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
466.3 µg/mL
[L54521]…
Half-life
25.5 days
Volume of distribution
4.1 L
[L54521]
Clearance
0.11 L
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]
[L50617]
It is also used to treat follicular lymphoma (FL), in combination with [bendamustine] followed by monotherapy, in patients who relapsed after or are refractory to, a [rituximab]-containing regimen.
[L50617]
It is used in combination with chemotherapy followed by monotherapy to treat previously untreated stage II bulky, III or IV follicular lymphoma in adult patients achieving at least a partial remission.
[L50617]
Obinutuzumab is indicated for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy.
[L54521]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1126 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L54521]
The Ctrough was 192.5 µg/mL in patients with CLL, 295 µg/mL in patients with relapsed or refractory FL, and 0.91 µg/mL in patients with LN.
[L54521]
The AUC was 8701 µg/mL x day in patients with CLL, 11362 µg/mL x day in patients with relapsed or refractory FL, and 8770 µg/mL x day in patients with LN.
[L54521]
[L54521]
[L54521]
[L54521]
Proteins and enzymes this drug interacts with in the body
PMID:12920111 PMID:3925015 PMID:7684739
Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR PMID:12920111 PMID:18474602 PMID:7684739
ATC L01FA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Obinutuzumab
Additional database identifiers
Drugs Product Database (DPD)
22546
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7315
GenAtlas
MS4A1
GeneCards
MS4A1
GenBank Gene Database
X12530
GenBank Protein Database
29774
Guide to Pharmacology
2628
UniProt Accession
CD20_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: